On March 31, Professor Qiao Renzhong from the College of Life Science and Technology at Beijing University of Chemical Technology visited Qidu Pharmaceutical for inspection, attended the cooperation signing ceremony and delivered a lecture. Chairman Zheng Jiaqing presented Professor Qiao with a consultant appointment certificate, while General Manager Zhang Jianyong presided over the ceremony. Senior Vice President Cui Liangfeng and Professor Qiao Renzhong signed the agreement on behalf of both parties. Company leaders Dong Xu and Hu Changqing, along with relevant personnel from the research institute and active pharmaceutical ingredients (API) division, participated in the event.

Professor Qiao Renzhong delivered an academic report titled "Green and Low-Carbon Production of APIs with Process Innovation." In his report, he emphasized that developing advanced green and low-carbon production technologies for APIs, establishing proprietary preparation processes, improving resource utilization efficiency in production, and continuously reducing energy consumption and emissions are crucial for promoting the green transformation of China's API industry and enhancing its international competitiveness. He outlined four current shifts in API project development: first, the changing model of generic drug development with rapidly growing influence of process advancement; second, the transformation of traditional CRO services with process competitiveness becoming paramount; third, the evolving development cycles and models where process importance is increasingly prominent; and fourth, the changing path of generic drug development where combining imitation with innovation will be the only way forward for generic drug R&D. He recommended continuously monitoring FDA-approved products, patent protection periods, and indications to conduct thorough product research. He also stressed the need to persistently optimize reaction conditions and steps while continuously improving and upgrading process solutions. Attendees engaged in a lively and in-depth discussion on the report's content, with Professor Qiao providing detailed answers to all questions raised.

Zheng Jiaqing welcomed Professor Qiao's visit, noting that his report demonstrated strong industry relevance, high academic value, and practical applicability. He urged all participants to systematically study the report's content and thoroughly grasp the innovative concepts and approaches for project initiation, technical challenges, and team building. Regarding the development of the API division, Zheng proposed the following directives: first, to consistently adhere to the development strategy integrating industry, academia, and research, actively exploring cooperation mechanisms between enterprises and universities in scientific research, information exchange, and talent cultivation; second, to establish in-depth collaborations with top-tier domestic and international universities and leading experts; and third, to further accelerate the development of Qidu Pharmaceutical's API business. Building on existing academic collaborations with universities and experts, the company should focus on three major product lines—green process research for small-molecule chemical APIs, macromolecular biochemical APIs, and inorganic salt mineral APIs—to achieve rapid breakthroughs and support the company's transformation and growth.

Founded in 1958 as Beijing Institute of Chemical Technology, Beijing University of Chemical Technology was established by the People's Republic of China to "cultivate advanced chemical engineering talent for cutting-edge scientific development." It is a prestigious university designated under the national 211 Project and 985 Advantage Discipline Innovation Platform," as well as a "Double First-Class" initiative institution. Professor Qiao Renzhong is a distinguished scholar in chemical biology and a doctoral supervisor. His research focuses on drug design, synthesis, and pharmacological activity studies, green production processes for high-end chemical products and generic drugs, and chemical biology. In recent years, he has led 10 National Natural Science Foundation projects and 5 major national pharmaceutical research initiatives. He has published over 80 SCI papers in renowned international pharmaceutical journals, holds 31 domestic and international patents, and has received 2 provincial/ministerial awards and 4 certified research achievements.